Routine vaccination of children with 1 dose of varicella vaccine led to a dramatic decrease in varicella (chickenpox) incidence and varicella-related morbidity and mortality in the United States (1) . By 2005, evidence suggested that the limits of control had been reached with the 1-dose childhood vaccination program (1) (2) (3) (4) . Consequently, in 2006, the Advisory Committee on Immunization Practices (ACIP) revised the varicella vaccine guidelines to include routine 2-dose vaccination for children by school entry with catch-up vaccination for those who had received a single dose (1) . The initial impact on varicella epidemiology of the routine 2-dose recommendation is unknown. In Connecticut, chickenpox has been a notifiable disease since 2001. Health care providers, licensed child daycare centers directors, and schools are required to report cases of chickenpox. Any report is accepted; laboratory confirmation is not required. Since 2000, the state has had child daycare and school entry requirements for 1 varicella vaccine dose or history of disease. Surveillance data were analyzed to assess the initial impact of the ACIP's 2006 routine 2-dose varicella vaccination recommendation. Reports for 2005, the last year before the new recommendations, and 2008, the most recent year with complete data, were analyzed for age-specific incidence. Cases from 2008 were also analyzed for vaccination status and history of chickenpox. Potentially preventable cases were defined as those cases that were not up to date according to the 2006 ACIP varicella vaccination guidelines. During 2001-2006, varicella incidence remained stable at approximately 50 cases per 100,000 population. In 2007, the rate began to decline. In 2008, the rate was 24.5 cases per 100,000 population and preliminary figures for 2009 show a further drop to13.9 cases/100,000 ( Figure 1, page 4 Day Care (n = 55,040)
The exemption rate (medical and religious) was 1.0%.
Kindergarten (n = 46,158)
The exemption rate (medical and religious) was 1.1%.
7
th Grade (n = 44,665)
The exemption rate (medical and religious) was 0.4%.
College (n = 40,214 for measles/rubella requirements, 49,539 for meningococcal requirement)
The Immunization Program thanks the day care providers, school nurses and other staff who complete these surveys and the immunization providers who keep Connecticut's children up-to-date with their immunizations. The surveys allow us to monitor immunization trends over time and to take corrective action as needed. We also report our results to the Centers for Disease Control and Prevention so Connecticut's results can be compared with those of other states. VaxFacts I m m u n i z a t i o n R e v i e w VaxFacts I m m u n i z a t i o n R e v i e w 
New College Requirements
Beginning August 1, 2010 all incoming freshman (full-time or matriculating) will be required to show proof of 2 doses of measles, mumps and rubella vaccine and 2 doses of varicella (chickenpox) vaccine. For more information on the college requirements, click on this link to our memo posted on the DPH website: http://www.ct.gov/dph/lib/dph/infectious_diseases/ immunization/2010/college_immunization_regs_guidance_5_6_2010.pdf
No Benefit to Delaying Immunizations
Some parents concerned that their children are receiving too many vaccines at too young an age are requesting doctors to postpone their children's immunizations. A study examined data from the U.S. Vaccine Safety Datalink found that delaying vaccines has no benefit with regards to children's long-term mental development and can increase the incidence of vaccine-preventable diseases. The study examined test results from over 1,000 children vaccinated from 1993 to 1997 and compared their results for a group vaccinated on time with a group that had delayed immunizations. The results of the tests showed that timely vaccination during infancy had no adverse effects on neuropsychological outcomes 7 to 10 years later. For more details, see the complete report in the June 2010 issue of Pediatrics. 
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The incidence and number of cases remain highest in children aged <15 years. On Feb 24 th of this year, Wyeth Vaccines (now Pfizer) licensed a new version of the pneumococcal conjugate vaccine that added six additional serotypes of protection against invasive pneumococcal disease (IPD). IPD incidence was reported to be on the rise again due in large part to the prevalence of antigenic serotype 19A, which is now included in the vaccine. The ACIP recommendations advise a full switch over to the newly licensed PCV13.
GO
Children not previously vaccinated should be started on PCV13 SLOW Children in progress should complete their series with PCV13 STOP then GO Children less than 5 years old who have already received 4 doses of PCV7 should receive a dose of PCV13 eight weeks after their last PCV7 dose to afford them protection against the six additional serotypes.
The full ACIP Recommendations on PCV13 can be found at: www.cdc.gov/vaccines/ recs/provisional/downloads/pcv13-mar-2010-508.pdf among school-aged children and are potentially preventable. Thus, the 2-dose regimen can be expected to have further substantial impact on reducing varicella incidence. Disease incidence paradoxically increased slightly among infants, older adolescents, and adults, groups not directly targeted by the new recommendations. The reasons for these increases are unclear, but may indicate that the number of children vaccinated with 2 doses is not yet sufficient to reduce spread in the community. Continued monitoring of these groups is needed to determine whether the observed increase persists. Disease appears to be occurring among persons who have been vaccinated with 2 doses of varicella vaccine, a finding that was observed in studies comparing children vaccinated with 1 or 2 doses (5). It is unclear how many of these cases represent true varicella disease as laboratory confirmation is not required. This observation raises the question as to whether 2 doses will be sufficient to totally stop community-level varicella transmission. Further observation is needed to answer this question as the number of 2-dose recipients increases. This analysis suggests that routine 2-dose vaccination is an effective varicella prevention strategy. A regulatory change is currently pending in Connecticut to modify the school-based vaccination requirement from 1 to 2 varicella vaccine doses. This legislation is expected to help realize the full potential of the 2-dose varicella vaccination recommendation.
